Methods and compositions for inhibiting the effects of amyloid beta oligomers

Patent metadata

Field	Value
Publication number	US-10138286-B2
Application number	US-201414772357-A
Country	US
Kind code	B2
Filing date	Mar 10, 2014
Priority date	Mar 12, 2013
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

Methods and compositions are provided for reducing the effects of amyloid beta (Aβ) oligomers on a cell. Aspects of the methods generally include providing an agent that prevents Aβ oligomer activation of PirB/LILRB2 protein on cells, or providing a PirB/LILRB2 polypeptide composition to cells to prevent the Aβ oligomer activation of cells mediated by non-PirB/LILRB2 receptors. These methods find many uses, for example, in treating the decline in CNS function in individuals suffering from an Aβ-associated disease or disorder, and for screening candidate agents to identify new therapeutics that interfere with these toxic effects of Aβ in individuals having an Aβ-associated disease or disorder.

First claim

That which is claimed is:

1. A composition comprising a LILRB2 polypeptide consisting of the first two Ig-like domains of LILRB2, which are residues 24-223 of SEQ ID NO: 3; and an Fc domain.

2. A composition comprising a polypeptide dimer, the dimer comprising: a first polypeptide, which comprises a dimerizing Fc domain fused to a LILRB2 polypeptide consisting of the first two Ig-like domains of LILRB2, which are residues 24-223 of SEQ ID NO: 3; and a second polypeptide, which comprises a dimerizing Fc domain fused to a LILRB2 polypeptide consisting of the first two Ig-like domains LILRB2, which are residues 24-223 of SEQ ID NO: 3.

3. The composition according to claim 2 , wherein the dimerizing Fc domain is human IgG1-Fc.

Assignees

• Univ Leland Stanford Junior

Inventors

• Shatz Carla J
• Kim Taeho

Classifications

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title

• C07K14/70503 Primary

  Immunoglobulin superfamily · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title